Durability of the First Biologic in Patients with Crohn's Disease: A Nationwide Study from the epi-IIRN.

MLA

Atia, Ohad, et al. “Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the Epi-IIRN.” Journal of Crohn’s & Colitis, vol. 18, no. 1, Jan. 2024, pp. 38–46. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjad121.

APA

Atia, O., Friss, C., Focht, G., Rimon, R. M., Ledderman, N., Greenfeld, S., Ben-Tov, A., Weisband, Y. L., Matz, E., Gorelik, Y., Chowers, Y., Dotan, I., & Turner, D. (2024). Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the epi-IIRN. Journal of Crohn’s & Colitis, 18(1), 38–46. https://doi.org/10.1093/ecco-jcc/jjad121

Chicago

Atia, Ohad, Chagit Friss, Gili Focht, Ramit Magen Rimon, Natan Ledderman, Shira Greenfeld, Amir Ben-Tov, et al. 2024. “Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the Epi-IIRN.” Journal of Crohn’s & Colitis 18 (1): 38–46. doi:10.1093/ecco-jcc/jjad121.